

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY[®]

EDITORIAL

Vancomycin-Intermediate *Staphylococcus epidermidis*: Curio or Omen?

LARRY J. STRAUSBAUGH, MD

163

ORIGINAL ARTICLES

The Emergence of Decreased Susceptibility to Vancomycin in *Staphylococcus epidermidis*

DENISE O. GARRETT, MD; ELISE JOCHIMSEN, MD; KATE MURFITT, BS; BERTHA HILL, BS; SIGRID McALLISTER, BS; PAT NELSON, RN; RICHARD V. SPERA, MD; RICHARD K. SALL, MD; FRED C. TENOVER, PhD; JUDY JOHNSTON, MS; BARBARA ZIMMER, PhD; WILLIAM R. JARVIS, MD

167

The Prevalence of Colonization With Vancomycin-Resistant *Enterococcus* at a Veterans' Affairs Institution

JEROME I. TOKARS, MD, MPH; SACHIKO SATAKE, PhD; DAVID RIMLAND, MD; LORETTA CARSON, MS; ELAINE R. MILLER, RN, MPH; EDNA KILLUM, RN; RONDA L. SINKOWITZ-COCHRAN, BS, MPH; MATTHEW J. ARDUINO, DrPH; FRED C. TENOVER, PhD; BARBARA MARSTON, MD; WILLIAM R. JARVIS, MD

171

Management of a Sabiá Virus-Infected Patient in a US Hospital

LORI R. ARMSTRONG, PhD; LOUISE-MARIE DEMBRY, MD; PETRIE M. RAINEY, MD, PhD; MARK B. RUSSI, MD; ALI S. KHAN, MD; STEVEN H. FISCHER, MD, PhD; STEPHEN C. EDBERG, PhD; THOMAS G. KSIAZEK, DVM, PhD; PIERRE E. ROLLIN, MD; C.J. PETERS, MD

176

Surgical-Site Complications Associated With a Morphine Nerve Paste Used for Postoperative Pain Control After Laminectomy

MICHAEL H. KRAMER, MD, MPH; ALICIA J. MANGRAM, MD; MICHELE L. PEARSON, MD; WILLIAM R. JARVIS, MD

183

Epidemiology of Device-Associated Infections Related to a Long-Term Implantable Vascular Access Device

MARK J. SOTIR, MPH; CURTIS LEWIS, MD; EDWARD W. BISHER, MD; SUSAN M. RAY, MD; J. MICHAEL SOUCIE, PhD; HENRY M. BLUMBERG, MD

187

Long-Lasting Contamination of a Vitrectomy Apparatus With *Serratia marcescens*

INES KAPPSTEIN, MD; CHRISTIAN M. SCHNEIDER, MD; HAJO GRUNDMANN, MD; REGINA SCHOLZ, RN, ICP; PETER JANKNECHT, MD

192

Evaluation of the SENIC Risk Index in a Spanish University Hospital

VICTORIA VALLS, MD; MANUEL DIEZ, MD; JAVIER ENA, MD; ALBERTO GUTIÉRREZ, MD; PEÑA GÓMEZ-HERRUZ, MD; ANTONIO MARTÍN, MD; ROSARIO GÓNZALEZ-PALACIOS, PHARM D; JAVIER GRANELL, MD

196

CONCISE COMMUNICATIONS

Evaluation of a Handwashing Intervention to Reduce Respiratory Illness Rates in Senior Day-Care Centers

ANN R. FALSEY, MD; MARY M. CRIDDLE, RN; JOHN E. KOLASSA, PhD; ROBERT M. McCANN, MD; CHRISTINE A. BROWER, BS; WILLIAM J. HALL, MD

200

Regional Dissemination and Control of Epidemic Methicillin-Resistant *Staphylococcus aureus*

LINDSAY E. NICOLLE, MD; BRENDA DYCK, BScN; GENEVIEVE THOMPSON, RN; SUSAN ROMAN, MD; AMIN KABANI, MD; PIERRE PLOURDE, MD; MARGARET FAST, MD; JOHN EMBIL, MD; THE MANITOBA CHAPTER OF CHICA-CANADA

202

Continued inside.

Are You Doing All You Can to Stop Methicillin-Resistant *Staphylococcus aureus* Outbreaks Where They Originate...

The Nares

- *Bactroban* Nasal is indicated for eradication of nasal colonization with methicillin-resistant *S. aureus* (MRSA) in adult patients and healthcare workers as part of a comprehensive infection control program to reduce the risk of infection among high-risk patients during MRSA outbreaks.¹
- In a hospital study, *Bactroban* Nasal contributed to a dramatic reduction in MRSA infections and vancomycin costs during an outbreak.²
- Excellent safety profile¹

Single-use tube
(actual size)



Please see brief summary of prescribing information on adjacent page.

References: 1. Bactroban® Nasal prescribing information, 1995. 2. Reagan DR, Dula RT, Palmer BH, et al. Control of MRSA in a VAMC with limited resources. Prog Abstr 31st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, U.S.A., Sept. 29-Oct. 2, 1991, p 104.

SB SmithKline Beecham
Pharmaceuticals

Bactroban®
Nasal mupirocin
calcium

2% ointment for intranasal use

BACTROBAN® NASAL (mupirocin calcium ointment), 2%
Brief summary. For complete prescribing information, see package insert.

INDICATIONS AND USAGE

Bactroban Nasal is indicated for eradication of nasal colonization with methicillin-resistant *Staphylococcus aureus* in adult patients and health care workers as part of a comprehensive infection control program to reduce the risk of infection among patients at high risk of methicillin-resistant *S. aureus* infection during institutional outbreaks of infections with this pathogen.

NOTE:

- (1) There are insufficient data at this time to establish that this product is safe and effective as part of an intervention program to prevent autoinfection of high-risk patients from their own nasal colonization with *S. aureus*.
- (2) There are insufficient data at this time to recommend use of *Bactroban* Nasal for general prophylaxis of any infection in any patient population.
- (3) Greater than 90% of subjects/patients in clinical trials had eradication of nasal colonization 2 to 4 days after therapy was completed. Approximately 30% recolonization was reported in one domestic study within 4 weeks after completion of therapy. These eradication rates were clinically and statistically superior to those reported in subjects/patients in the vehicle-treated arms of the adequate and well-controlled studies. Those treated with vehicle had eradication rates of 5% to 30% at 2 to 4 days post-therapy with 85% to 100% recolonization within 4 weeks.

CONTRAINDICATIONS

Bactroban Nasal is contraindicated in patients with known hypersensitivity to any of the constituents of the product.

WARNINGS

AVOID CONTACT WITH THE EYES. Application of *Bactroban* Nasal to the eye under testing conditions has caused severe symptoms such as burning and tearing. These symptoms resolved within days to weeks after discontinuation of the ointment.

In the event of a sensitization or severe local irritation from *Bactroban* Nasal, usage should be discontinued.

PRECAUTIONS

General: As with other antibacterial products, prolonged use may result in overgrowth of nonsusceptible microorganisms, including fungi. (See DOSAGE AND ADMINISTRATION in complete prescribing information.)

Information for Patients: Patients should: apply approximately one-half of the ointment from the single-use tube directly into one nostril and the other half into the other nostril; avoid contact of the medication with the eyes; discard the tube after using; press the sides of the nose together and gently massage after application to spread the ointment throughout the inside of the nostrils; and discontinue using *Bactroban* Nasal and call a health care practitioner if sensitization or severe local irritation occurs.

Drug Interactions: The effect of the concurrent application of intranasal mupirocin calcium and other intranasal products has not been studied. Do not apply mupirocin calcium ointment, 2% concurrently with any other intranasal products.

Carcinogenesis, Mutagenesis, Impairment of Fertility: Long-term studies in animals to evaluate carcinogenic potential of mupirocin calcium have not been conducted. Results of the following studies performed with mupirocin calcium or mupirocin sodium *in vitro* and *in vivo* did not indicate a potential for mutagenicity: rat primary hepatocyte unscheduled DNA synthesis, sediment analysis for DNA strand breaks, *Salmonella* reversion test (Ames), *Escherichia coli* mutation assay, metaphase analysis of human lymphocytes, mouse lymphoma assay, and bone marrow micronuclei assay in mice. Reproduction studies were performed in rats with mupirocin administered subcutaneously at doses up to 40 times the human intranasal dose (approximately 20 mg mupirocin per day) on a mg/m² basis and revealed no evidence of impaired fertility from mupirocin sodium.

Pregnancy: Teratogenic Effects. Pregnancy Category B. Reproduction studies have been performed in rats and rabbits with mupirocin administered subcutaneously at doses up to 65 and 130 times, respectively, the human intranasal dose (approximately 20 mg mupirocin per day) on a mg/m² basis and revealed no evidence of harm to the fetus due to mupirocin. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

Nursing Mothers: It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, exercise caution when *Bactroban* Nasal is administered to a nursing woman.

Pediatric Use: Safety in children under the age of 12 years has not been established. (See CLINICAL PHARMACOLOGY in complete prescribing information.)

ADVERSE REACTIONS

Clinical Trials: In clinical trials, 210 domestic and 2,130 foreign adult subjects/patients received *Bactroban* Nasal ointment. Less than 1% of domestic or foreign subjects and patients in clinical trials were withdrawn due to adverse events. In domestic clinical trials, 17% (36/210) of adults treated with *Bactroban* Nasal ointment reported adverse events thought to be at least possibly drug-related. The incidence of adverse events thought to be at least possibly drug-related that were reported in at least 1% of adults enrolled in domestic clinical trials were as follows: headache, 9%; rhinitis, 6%; respiratory disorder, including upper respiratory tract congestion, 5%; pharyngitis, 4%; taste perversion, 3%; burning/stinging, 2%; cough, 2%; and pruritus, 1%.

The following events thought possibly drug-related were reported in less than 1% of adults enrolled in domestic clinical trials: blepharitis, diarrhea, dry mouth, ear pain, epistaxis, nausea and rash. All adequate and well-controlled clinical trials have been performed using *Bactroban* Nasal ointment, 2% in one arm and the vehicle ointment in the other arm of the study.

OVERDOSAGE

Following single or repeated intranasal applications of *Bactroban* Nasal to adults, no evidence for systemic absorption of mupirocin was obtained.

Manufactured by **DPT Laboratories, Inc.**, San Antonio, TX 78215

Distributed by **SmithKline Beecham Pharmaceuticals**, Philadelphia, PA 19101

BN:L1

Good medicine for your career

At St. Rita's Medical Center, a 400+ bed regional referral center located in West Central Ohio, human dignity, compassionate care and advanced medical technologies combine to provide the highest quality care. Discover professional rewards and personal satisfaction in a team-oriented environment.

Infection Control Coordinator


Full Time

We have an immediate full time opportunity for an Infection Control Coordinator to manage the hospital-wide Infection Control program. Responsibilities will include originating and reviewing policies and procedures; functioning as a resource for physicians, staff, and patients; assuring compliance with regulatory guidelines; and providing orientation and continuing education for staff members.

Successful candidates must have a minimum of a B.S. degree with Medical Technology registration or an R.N. license with demonstrated problem solving, communication and data analysis skills. Knowledge of Epidemiologic Principles, sterilization and disinfection procedures also required. Must have familiarity with patient care equipment and procedures, as well as knowledge of, and experience with, state, federal and JCAHO regulations. CIC certification in Infection Control, or willing to obtain, will be required.

We offer salary commensurate with experience and flexible benefits. Qualified candidates may apply in person, or mail/fax/email resume to: **Employment Manager, St. Rita's Medical Center**, 730 W. Market St., Lima, OH 45801, PH: (419) 226-9548 or 1-800-232-7762 ext. 9548, FAX: (419) 226-9870, Email: javantilburgh@health-partners.org

St. Rita's is an equal opportunity employer.



St. Rita's
MEDICAL
CENTER

MEDICAL MATRIX

Ranked, Peer-Reviewed,
Annotated, Updated,
Clinical Medicine Resources

- MEDLINE
- JOURNALS
- CME
- NEWS
- RX ASSIST
- TEXTBOOKS
- STAT SEARCH NEW!
- PATIENT EDUCATION
- MARKETPLACE

**THE LARGEST PEER-REVIEWED,
ANNOTATED AND RATED INTERNET
MEDICAL DIRECTORY**

**VISIT MEDICAL MATRIX FOR
FREE ACCESS TO THE BEST
MEDICAL SITES ON THE WEB**

<http://www.medmatrix.org>
(Registration Required)

Reviewed and updated continuously by an Editorial
Board comprised of Physicians and Medical
Informatics Specialists

For advertising opportunities contact M. Long



The Society for Healthcare Epidemiology of America

1999 SHEA/CDC Training Course in Hospital Epidemiology

Program

The program will be held May 1-4, 1999 at the Wyndham Franklin Plaza Hotel, Philadelphia, Pennsylvania. Timothy W. Lane, M.D., Gina Pugliese, R.N., and Julie Gerberding, M.D. will chair the program.

Purpose

This program, developed by the Society for Healthcare Epidemiology of America (SHEA), and the Centers for Disease Control and Prevention (CDC), is intended for infectious disease fellows and new hospital epidemiologists. It emphasizes hands-on exercises in which participants work in small groups to detect, investigate, and control epidemiological problems encountered in the hospital setting. These work sessions are supplemented with lectures and seminars covering fundamental aspects of hospital epidemiology and surveillance, epidemic investigation, transmission and control of nosocomial infections, disinfection and sterilization, employee health, isolation systems, regulatory compliance, and quality improvement.

Who Should Attend

You should attend if you are a hospital epidemiologist or an infection control practitioner or if you are looking for a course that will provide you the most current information concerning infection control practices and epidemiological methods in health care. This fundamental program will provide you with the opportunities to find solutions to real situations that will occur in the hospital setting. Intensive problem solving sessions are supplemented with lectures and seminars presented by leading authorities.

Scholarships

Scholarships in the amount of \$1,000 will be awarded to infectious disease fellows for the program to defray the special course fee for fellows of \$350 and expenses incurred in attending the training program.

Interested fellows must submit a letter of no more than one page describing why they would like to have additional training in hospital epidemiology. A letter from the fellow's program director outlining the applicant's qualifications and suitability for the course also is required. The deadline for receipt of scholarship applications for the course is March 26, 1998.

The SHEA Educational Activities Committee will select the scholarship recipients based on review of these letters. Winners will be notified in September.

Nominations

Please send scholarship applications to:

Timothy W. Lane, M.D.
c/o The Society for Healthcare Epidemiology of America
19 Mantua Road
Mt. Royal, NJ 08061

Fees

Individual Registrants	\$495
Fellows in Infectious Disease	\$350

Credits

The Society for Healthcare Epidemiology of America (SHEA) is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians.

SHEA designates this continuing education activity for up to 23 hours in Category 1 of the Physician's Recognition Award of the American Medical Association.

The SHEA/CDC Training Course is AACN (American Association of Critical Care Nurses) approved for 28.5 hours.

General Course Information

Information regarding the schedule, hotel and travel accommodations, discount airfare, and course fees are available from SHEA (609) 423-7222 x350. Note that application for a scholarship does not constitute enrollment in the program. This must be done separately.

Scholarship Awards provided in part by an educational grant from Pfizer Pharmaceuticals.



Labs • NHO • Pratt • Roerig • Specialty
U.S. Pharmaceuticals Group

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY®

CONTENTS

Continued from cover

Nosocomial Infections With Ceftazidime-Resistant***Pseudomonas aeruginosa*: Risk Factors and Outcome**SAI-CHEONG LEE, MD; CHANG-PHONG FUNG, MD; PETER YUK-FONG LIU, MD, MSc; TZU-CHIEN WANG, PhD;
LAI-CHU SEE, PhD; NING LEE, MD; SHU-CHU CHEN, RN; WEN-BIN SHIEH, MD

205

THE INTERNATIONAL PERSPECTIVE**The Effect of Frequency of Chart Review on the Sensitivity
of Nosocomial Infection Surveillance in General Surgery**MIGUEL DELGADO-RODRÍGUEZ, MD, PhD; ANTONIO GÓMEZ-ORTEGA, MD; ANTONIO SIERRA, MD, PhD;
TRINIDAD DIERSEN, MD; JAVIER LLORCA, MD, PhD; MARÍA SILLERO-ÁRENAS, MD, PhD

208

LETTERS TO THE EDITOR**Hepatitis B and Hemodialysis: The Impact of Universal Precautions in
Preventing the Transmission of Bloodborne Viruses (with reply)**ROB LYERLA, PhD; SCOTT KELLERMAN, MD, MPH; MIRIAM J. ALTER, PhD; ALOYS C.M. KROES, MD, PhD;
ERIC F.H. VAN BOMMEL, MD, PhD; JAN A.J.W. KLUYTMANS, MD, PhD; WILLEM WEIMAR, MD, PhD

156

Risk of Tuberculosis Transmission in an Adult Day-Care Center

JUDITH E. WOLF, MD; JAMES L. DEAN, MD

157

**Level of Suspicion of Pulmonary Tuberculosis Over a 4-Year Period
in a Teaching Hospital**

ANNIE-CLAUDE LABBÉ, MD; KARL WEISS, MD, FRCPC; MICHEL LAVERDIÈRE, MD, FRCPC; LOUISE POIRER, MD, FRCPC

158

**Tuberculosis Contact Tracing Among Healthcare Workers:
Source-Case Selection, Method of Tracing, and Outcome of Follow-Up**

JOSEPH BARAN, JR, MD; HITPREET SANGHERA, MD; RIAD KHATIB, MD

160

MEDICAL NEWS

GINA PUGLIESE, RN, MS; MARTIN S. FAVERO, PhD

213

SHEA NEWS

ANDREAS VOSS, MD, PhD

216

To view abstracts of these articles,
visit us on the Internet at <http://www.slackinc.com/general/iche>

THE PUBLICATION OF ADVERTISING IN THE JOURNAL DOES NOT CONSTITUTE ANY GUARANTEE OR ENDORSEMENT BY THE SOCIETY FOR HEALTHCARE EPIDEMIOLOGY OF AMERICA OR SLACK INCORPORATED OF THE ADVERTISED PRODUCT OR SERVICE OR OF CLAIMS MADE BY THE ADVERTISER. THE PUBLICATION OF ARTICLES AND OTHER EDITORIAL MATERIAL IN THE JOURNAL DOES NOT NECESSARILY REPRESENT THE POLICY RECOMMENDATIONS OR ENDORSEMENT BY THE SOCIETY.

PUBLISHER: Infection Control and Hospital Epidemiology (ISSN-0899-823X, Canadian GST#129780466) is published exclusively by SLACK Incorporated 12 times a year. Address: 6900 Grove Rd., Thorofare, NJ 08086. Telephone: (609) 848-1000.

SHEA: 19 Mantua Rd., Mt. Royal, NJ 08061; telephone, 609-423-0087; fax, 609-423-3420; e-mail address, sheahq@talley.com.

COPYRIGHT 1999 The Society for Healthcare Epidemiology of America, Inc., and SLACK Incorporated. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. Printed in the USA.

SUBSCRIPTIONS: Requests should be addressed to the publisher (except Japan). In Japan, contact Woodbell Incorporated, 4-22-11, Kitakasai, Edogawaku, Tokyo 134, Japan. Subscription rates in the United States and possessions: Individual: One year-\$105.00; Two years-\$143.00; Three years-\$176.00; Institutional: One year-\$128.00; Two years-\$178.00; Three years-\$228.00. Fellows: \$52.50 per year with proof of training status. Canada: \$20.00 additional each year plus 7% for Canadian Goods & Services tax; Overseas surface, \$145.00 each year; Overseas air mail, \$190.00. Single copies of current issues may be obtained for \$15.00, United States and possessions; \$20.00 all other countries.

INSTRUCTIONS TO AUTHORS: Authors may submit manuscripts prepared in accordance with the 1997 revision of the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals." The Uniform Requirements has been published in several journals, including *Infect Control Hosp Epidemiol* 1997;18:457-464 and *Ann Intern Med* 1997;126:36-47. A digital version is available on our web site (<http://www.slackinc.com/general/iche/ichehome.htm>). Submit to ICHE Editorial Offices, Vanderbilt University School of Medicine, A-1131 Medical Center North, Nashville, TN 37232-2637, USA. All submissions must be accompanied by copyright form(s) signed by all authors (see January issue or our web site).

REPRINTS: All requests to reprint or use material published herein should be addressed to Karen Lambertson, SLACK Incorporated, 6900 Grove Rd., Thorofare, NJ 08086. For reprint orders and prices, contact Karen Lambertson at (609) 848-1000. Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by SLACK Incorporated, provided that the base fee of \$1.00 per copy, plus \$.15 per page is paid directly to Copyright Clearance Center, 27 Congress St., Salem, MA 01970. This consent does not extend to other kinds of copying, such as for general distribution, resale, advertising and promotional purposes, or for creating new collective works.

CHANGE OF ADDRESS: Notice should be sent to the publisher 6 weeks in advance of effective date. Include old and new addresses with zip codes. The publisher cannot accept responsibility for undelivered copies. Periodicals postage paid at Thorofare, New Jersey 08086-9447 and at additional mailing offices. POSTMASTER: Send address changes to SLACK Incorporated, 6900 Grove Rd., Thorofare, NJ 08086.

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY is listed in Index Medicus, Current Contents-Clinical Practice, Hospital Literature Index, Cumulative Index to Nursing & Allied Health Literature, Nursing Abstracts, Laboratory Performance Information Exchange System, and Rndex Top 100.

NOW AVAILABLE ON CD-ROM:

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY

1987-1997

Simplifying your reference library is easy, with 10 years of INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY now available on CD-ROM. As the official journal of the Society of Healthcare Epidemiology of America (SHEA), this ready reference will allow the user to quickly and easily access articles and studies from 1987-1997 that can help put current issues of epidemiology and infection control in perspective.

Easy and Convenient CD-ROM Technology

The INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY CD-ROM will take full advantage of the latest CD-ROM technology, including:

- fully searchable text
- annual indexes organized by category, page number, subject and author
- convenient annual updates
- PC and Mac compatibility

The INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY CD-ROM packs an enormous amount of information in a small space at a comparably small price! Adding 10 years of this informative journal to your library is a bargain, at special prices starting as low as \$147.

Money-Back Guarantee

The Society of Healthcare Epidemiology of America is always looking for innovative ways to keep you informed of important developments in infection control and hospital epidemiology. We are sure you will refer to the information in the INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY CD-ROM often. If you aren't satisfied, we offer a 30-day money-back guarantee.*

To order, call us at **800-257-8290** or **609-848-1000** (in NJ); or write to
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY
6900 Grove Rd., Thorofare, NJ 08086

Appx. pub. date: 10/98

☐ **Yes!** Please send me the INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY CD-ROM. Enclosed is a check or money order for the amount/quantity checked below.

☐ SHEA Member:	\$147.00 ea.	Qty: _____
☐ Individual Non-Member:	\$197.00 ea.	Qty: _____
☐ Institution:	\$247.00 ea.	Qty: _____

Or bill my ☐ Visa ☐ Mastercard ☐ Amex

Acct. No. _____ Exp. date: ____/____/____

Signature: _____

Send CD-ROM to:

Name _____

Address _____

City _____ State _____ Zip _____

Phone _____ FAX _____

Send order and make check payable to:

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY • 6900 Grove Rd. • Thorofare, NJ 08086

Or FAX your order to: (609) 853-5991

For fastest service, call today: 1-800-257-8290 or 609-848-1000 (in NJ)

Downloaded from <https://www.cambridge.org/core>. 12 Nov 2025 at 03:42:06, subject to the Cambridge Core terms of use. Exp: 4/99



*If not completely satisfied with the INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY CD-ROM, just return it within 30 days and your money will be refunded.

EDITORIAL OFFICES

Vanderbilt University School of Medicine
A-1131 Medical Center North
Nashville, TN 37232-2637
(615) 343-1095; (615) 343-1882 (FAX)
Email: iche@mcm.vanderbilt.edu

EDITOR

Michael D. Decker, MD, MPH

MANAGING EDITOR

Susan Cantrell

STATISTICAL EDITOR

Beverly G. Mellen, PhD

SENIOR ASSOCIATE EDITORS

C. Glen Mayhall, MD

Gina Pugliese, RN, MS

William Schaffner, MD

ASSOCIATE EDITORS

Donald A. Goldmann, MD

Didier Pittet, MD, MS

Andreas Widmer, MD, MS

SECTION EDITORS**Beyond Infection Control:****The New Hospital Epidemiology**

Bryan P. Simmons, MD

Stephen B. Kritchevsky, PhD

Memphis, Tennessee

Wing Hong Seto, MD

Hong Kong

Disinfection and Sterilization

William A. Rutala, PhD, MPH

Chapel Hill, North Carolina

Emerging Infectious Diseases

Larry J. Strausbaugh, MD

Portland, Oregon

Robert W. Pinner, MD

Atlanta, Georgia

From the Laboratory

Marcus Zervos, MD

Royal Oak, Michigan

Fred C. Tenover, PhD

Atlanta, Georgia

Information Management

John A. Sellick, DO

Buffalo, New York

The International Perspective

Mary D. Nettleman, MD, MS

Richmond, Virginia

Issues in Surgery

James T. Lee, MD, PhD

St. Paul, Minnesota

Medical News

Gina Pugliese, RN, MS

Chicago, Illinois

Martin S. Favero, PhD

Irvine, California

Practical Healthcare Epidemiology

Loreen A. Herwaldt, MD

Iowa City, Iowa

SHEA News

Andreas Voss, MD, PhD

Nijmegen, The Netherlands

Statistics for Hospital Epidemiology

David Birnbaum, PhD, MPH

Sidney, British Columbia, Canada

Topics in Long-Term Care

Philip W. Smith, MD

Omaha, Nebraska

Topics in Occupational Medicine

David Weber, MD, MPH

Chapel Hill, North Carolina

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY™

EDITORIAL ADVISORY BOARD

- | | |
|--------------------------------------|---|
| Jacques F. Acar, MD | Paris, France |
| J. Wesley Alexander, MD | Cincinnati, Ohio |
| Paul Arnow, MD | Chicago, Illinois |
| Graham A.J. Ayliffe, MD | Birmingham, United Kingdom |
| Neil L. Barg, MD | Yakima, Washington |
| Elizabeth Ann Bolyard, RN, MPH, CIC | Atlanta, Georgia |
| John M. Boyce, MD | Providence, Rhode Island |
| Professor Dr. Ilja Braveny | Munich, Federal Republic of Germany |
| Charles Bryan, MD | Columbia, South Carolina |
| Christian Brun-Buisson, MD | Creteil, France |
| Donald E. Craven, MD | Boston, Massachusetts |
| Sue Crow, MSN, RN, CIC | Shreveport, Louisiana |
| Franz Daschner, MD | Freiburg, Federal Republic of Germany |
| Leigh G. Donowitz, MD | Charlottesville, Virginia |
| Charles E. Edmiston, Jr., PhD | Milwaukee, Wisconsin |
| Theodore C. Eickhoff, MD | Denver, Colorado |
| Bruce Farber, MD | Manhasset, New York |
| Victoria J. Fraser, MD | St. Louis, Missouri |
| Peter C. Fuchs, MD, PhD | Black Butte, Oregon |
| Richard A. Garibaldi, MD | Farmington, Connecticut |
| Velvi Greene, PhD, MPH | Beer Sheva, Israel |
| Robert Gaynes, MD | Atlanta, Georgia |
| David W. Gregory, MD | Nashville, Tennessee |
| David K. Henderson, MD | Bethesda, Maryland |
| Peter N.R. Heseltine, MD | Los Angeles, California |
| Karen Hoffmann, RN, CIC, MS | Chapel Hill, North Carolina |
| Marguerite McMillan Jackson, RN, PhD | San Diego, California |
| Janine Jagger, MPH, PhD | Charlottesville, Virginia |
| William R. Jarvis, MD | Atlanta, Georgia |
| Douglas S. Kernodle, MD | Nashville, Tennessee |
| Robert H. Latham, MD | Nashville, Tennessee |
| Lewis B. Lefkowitz, MD | Nashville, Tennessee |
| Hsieh-Shong Leu, MD, MSc | Taipei, Taiwan |
| Jack Levy, MD | Brussels, Belgium |
| Victor Lorian, MD | Bronx, New York |
| Dennis G. Maki, MD | Madison, Wisconsin |
| Professor Dr. Walter Marget | Munich, Federal Republic of Germany |
| William J. Martone, MD | Bethesda, Maryland |
| Allison McGeer, MD | Toronto, Ontario, Canada |
| John E. McGowan, Jr., MD | Atlanta, Georgia |
| Jonathan L. Meakins, MD, DSc | Montreal, Quebec, Canada |
| Raf Mertens, MD | Brussels, Belgium |
| Robert R. Muder, MD | Pittsburgh, Pennsylvania |
| Joseph M. Mylotte, MD, CIC | Buffalo, New York |
| Lindsay Nicolle, MD | Winnipeg, Manitoba, Canada |
| Juhani Ojajarvi, MD | Helsinki, Finland |
| Michael T. Osterholm, PhD, MPH | Minneapolis, Minnesota |
| Jan Evans Patterson, MD | San Antonio, Texas |
| Sindy M. Paul, MD | Trenton, New Jersey |
| Michael A. Pfaller, MD | Iowa City, Iowa |
| Samuel Ponce de Leon, MD, MSc | Mexico City, Mexico |
| Isaam Raad, MD | Houston, Texas |
| Manfred L. Rotter, MD, DipBact | Vienna, Austria |
| Theodore Sacks, MD | Jerusalem, Israel |
| William E. Scheckler, MD | Madison, Wisconsin |
| Kent Sepkowitz, MD | New York City, New York |
| Denis Spelman, MD | Prahran Victoria, Australia |
| Michael L. Tapper, MD | New York, New York |
| Clyde Thornberry, PhD | Brentwood, Tennessee |
| Professor Leonid P. Titov | Minsk, Republic of Belarus |
| Timothy R. Townsend, MD | Millwood, Virginia |
| Antoni Trilla, MD, PhD | Barcelona, Spain |
| Professor Wang Shu-Qun | Beijing, People's Republic of China |
| J. John Weems, Jr., MD | Greenville, South Carolina |
| Robert A. Weinstein, MD | Chicago, Illinois |
| Professor Dr. W. Weuffen | Greifswald, Federal Republic of Germany |
| Sergio B. Wey, MD | São Paulo, Brazil |
| Rebecca Wurtz, MD | Evanston, Illinois |

SLACK Incorporated

6900 Grove Road
Thorofare, New Jersey 08086
(609) 848-1000

Vice President/Group Publisher

Richard N. Roash

Publisher

John C. Carter

Editorial Director

Jennifer Kilpatrick

Production Editor

Shirley P. Strunk, ELS

Assistant Editor

Eileen C. Anderer

Circulation Manager

Lester J. Robeson, CCCP

Production Director

Christine Malin

Production Coordinator

Joanne Patterson

Publishing Director/ Advertising

Wayne McCourt

Pharmaceutical Group Sales Director

Michael LoPresti

Advertising Sales Representative

Jennine Kane


Classified/Recruitment Sales Manager

Kathy Huntley

Classified/Recruitment Sales Representative

Kelly Wark

Just Released!



- **Overarching goals and ethical principles you should adopt to guide your practice**
- **What you can do to educate yourself**
- **How to negotiate with the administration and communicate with colleagues**
- **How to develop policies and procedures**
- **How to develop a surveillance system**

Downloaded from <https://www.cambridge.org/core>. 12 Nov 2025 at 03:42:06, subject to the Cambridge Core terms of use.

SHEA

CDC Guidelines
for Surveillance
Prevention & Control
of Nosocomial
Infections

**All In One
Single Volume
for only \$99.⁰⁰***

Plus Shipping
& Handling

Urinary Tract Infections • Surgical Wound Infections
Handwashing and Environmental Control
Hospital Personnel • HIV and HBV Exposure-
Prone Procedures • Pneumonia Tuberculosis
Vancomycin Resistance • IV Device-Related
Infections • Isolation Precautions
HIV Post-Exposure Chemoprophylaxis
HCV Post-Exposure Prophylaxis
and Index of SHEA Position Papers

Foreword by Julia S. Garner, RN, MN

To Order Call 1-800-552-0076

International Orders 414-634-0806
E-mail ETNAComm@aol.com

* SHEA Journal Subscribers mention this ad for 10% discount.
Orders outside the U.S.A., Canada, & Mexico are \$175.00 each.

SJ198



9 out of 10 mice prefer the Consumer Information Catalog online. Just point and click your way to **www.pueblo.gsa.gov** and you'll find more than 250 free publications ready to read or download.

U.S. General Services Administration

Finding the source of an infection in hours, not days.

A university teaching hospital noted increased infections caused by an antibiotic-resistant strain of *Pseudomonas aeruginosa*. Physicians noted resistance to imipenem, but were perplexed because, of the patients who cultured positive for the strain, only 15% had received imipenem.

The RiboPrinter® Microbial Characterization System took only eight hours to genetically fingerprint isolates and revealed that 85% of the infected patients shared the identical strain of *P. aeruginosa*. When hospital epidemiologists found that 85% of these patients had been intubated in the Shock Trauma Center (STC), they knew the increased incidence was due to nosocomial transmission.

Environmental culturing turned up *P. aeruginosa* in a pipe leading to the faucet in the STC and the RiboPrinter® system revealed that it was the identical strain to the one found in the patients. A simple chlorine rinse of the pipe eradicated the organism and the infections did not return.

Only the RiboPrinter® system's precise, fast, strain-level typing could have enabled hospital staff to pinpoint their cleanup efforts at the source of the nosocomial infection, saving the hospital time and money and minimizing the suffering of patients.

What can the RiboPrinter® system do for you?
Find out. Call 1.800.863.6842.
In Europe, call +44 (0) 1926.404008.

Qualicon™
A DuPont Subsidiary



www.qualicon.com